Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2

Introduction The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related adverse event. Case presentation The patient...

Full description

Bibliographic Details

Published in:	IJU Case Reports
Main Authors:	Kazunori Iwasaki, Toshitaka Shin, Toru Inoue, Tadamasa Shibuya, Kenichi Hirai, Tadasuke Ando, Hiromitsu Mimata
Format:	Article
Language:	English
Published:	Wiley 2021-05-01
Subjects:	durable response immune‐related adverse event myeloradiculoneuropathy nivolumab papillary renal cell carcinoma
Online Access:	https://doi.org/10.1002/iju5.12262